Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / COM
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
3,541,963
-
Shares change
-
+885,257
-
Total reported value, excl. options
-
$6,489,816
-
Value change
-
+$1,630,735
-
Put/Call ratio
-
0%
-
Number of buys
-
16
-
Number of sells
-
-9
-
Price
-
$1.8
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q2 2025
41 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q2 2025.
Gain Therapeutics, Inc. - COM (GANX) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,541,963 shares
.
Largest 10 shareholders include JONES FINANCIAL COMPANIES LLLP (676,888 shares), DME Capital Management, LP (566,130 shares), VANGUARD GROUP INC (534,352 shares), GEODE CAPITAL MANAGEMENT, LLC (290,462 shares), MARSHALL WACE, LLP (276,433 shares), Cambridge Investment Research Advisors, Inc. (179,500 shares), CITADEL ADVISORS LLC (161,816 shares), BlackRock, Inc. (112,507 shares), NORTHERN TRUST CORP (100,170 shares), and RENAISSANCE TECHNOLOGIES LLC (94,000 shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.